ANNX - Annexon, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
South San Francisco,
United States
Type: Equity
ANNX price evolution
ANNX
| (in millions $) | 1 May 2023 | 31 Jan 2023 | 30 Oct 2022 | 30 Jul 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $232.54 | $248.1 | $274.78 | $181.37 |
| Long term investments | ||||
| Property, plant & equipment | $35.2 | $35.97 | $36.71 | $37.28 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $268.78 | $285.1 | $312.72 | $220.7 |
| Current liabilities | ||||
| Accounts payable | $10.35 | $7.42 | $6.92 | $10.3 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $22.94 | $22.36 | $20.22 | $20.25 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $53.92 | $53.9 | $52.12 | $52.66 |
| Shareholders' equity | ||||
| Retained earnings | -$476.94 | -$438.26 | -$403.88 | -$368.82 |
| Other shareholder equity | -$0.22 | -$0.37 | -$0.41 | -$0.44 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $268.56 | $43.93 | ||
| Short term investments | ||||
| Net receivables | $0.1 | |||
| Inventory | ||||
| Total current assets | $248.1 | $247.69 | $354.01 | $45.41 |
| Long term investments | ||||
| Property, plant & equipment | $35.97 | $38.18 | $1.94 | $2.14 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $1.94 | $4.49 | ||
| Total investments | ||||
| Total assets | $285.1 | $287.04 | $355.95 | $49.9 |
| Current liabilities | ||||
| Accounts payable | $7.42 | $11.15 | $3.73 | $2.37 |
| Deferred revenue | $0.39 | $0.37 | ||
| Short long term debt | ||||
| Total current liabilities | $22.36 | $21.74 | $10.62 | $4.93 |
| Long term debt | ||||
| Total noncurrent liabilities | $1.05 | $145.42 | ||
| Total debt | ||||
| Total liabilities | $53.9 | $55.13 | $11.67 | $150.35 |
| Shareholders' equity | ||||
| Retained earnings | -$438.26 | -$296.31 | -$165.99 | -$102.58 |
| Other shareholder equity | -$0.37 | -$0.18 | -$0.08 | -$0.08 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $36.07 | $37.41 | ||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$35.05 | -$37.14 | ||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | 30 Jan 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $63.47 | $32.52 | $19.15 | |
| Operating income | -$63.47 | -$32.52 | -$19.15 | |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0 | $0 | ||
| Interest expense | ||||
| Net income | ||||
| Net income | -$63.41 | -$37.18 | -$18.3 | |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $102.06 | $87.96 | $68.25 | -$88.24 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $122.8 | $0.13 | $0.02 | $1.79 |
| Effect of exchange rate | -$0.01 | -$0 | -$0.01 | |
| Change in cash and equivalents | $135.68 | $29.64 | $37.98 | -$192.57 |
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | 30 Jan 2019 |
|---|---|---|---|---|
| Net income | -$63.41 | -$37.18 | -$18.3 | |
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$53.09 | -$28.36 | -$17.19 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$88.24 | -$83.16 | -$0.27 | -$0.02 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $1.79 | $360.88 | $28.39 | $58.46 |
| Effect of exchange rate | -$0.01 | $0.01 | -$0.01 | -$0.04 |
| Change in cash and equivalents | -$192.57 | $224.63 | -$0.23 | $41.21 |
News
Fundamentals
| Market cap | $158.18M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 53.08M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 10.14 |
| Quick ratio | N/A |